Mydriacyl (Tropicamide)

Tropicamide works by competitively blocking muscarinic acetylcholine receptors, especially the M3 subtype, on the iris sphincter and ciliary muscles. This inhibition prevents parasympathetic‑mediated contraction, causing the sphincter muscle to relax (producing pupil dilation) and the ciliary muscle to lose tone (producing cycloplegia). The effect appears within minutes after topical administration and typically lasts several hours, providing a window for examination or surgery.

The dosage of Mydriacyl is determined by the prescribing eye‑care professional based on the specific clinical need, patient age, and ocular condition. Typically, one or two drops are instilled in the affected eye(s) and may be repeated after a short interval if greater dilation is required. Exact dosing frequency and quantity should follow the prescriber’s instructions and the product labeling.

Safety data for tropicamide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Because systemic absorption after ocular use is minimal, the drug is generally considered low risk, but it should only be used when clearly needed and after a risk‑benefit assessment by the treating physician. Breastfeeding mothers should consult their healthcare provider before use.

To request Mydriacyl, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Mydriacyl (tropicamide) is a short‑acting muscarinic antagonist that produces rapid onset of mydriasis and cycloplegia, typically lasting 4‑6 hours. Compared with longer‑acting agents such as atropine, tropicamide offers a shorter duration and lower risk of prolonged blurred vision. Phenylephrine, an adrenergic agonist, dilates the pupil via a different mechanism and may be combined with tropicamide for enhanced effect, but it does not provide cycloplegia.

Mydriacyl ophthalmic solution should be stored at room temperature, below 25 °C, in its original container protected from light and moisture. Keep the bottle tightly closed when not in use and avoid freezing. Do not use the product beyond the expiration date printed on the label, and discard any solution that appears discolored or contaminated.

Mydriacyl is applied topically as eye drops. The patient or clinician instills the prescribed number of drops into the conjunctival sac of the target eye(s), typically while the eye is closed for a few seconds to allow absorption. No systemic administration is required. The onset of pupil dilation usually occurs within 5‑15 minutes, with maximal effect reached in about 30 minutes.

The most serious adverse events linked to Mydriacyl are acute angle‑closure glaucoma and severe allergic reactions. Angle‑closure glaucoma can present as sudden eye pain, headache, nausea, and rapid vision loss, requiring immediate medical attention. Anaphylaxis or severe local hypersensitivity may manifest as eyelid swelling, rash, or urticaria. Patients with known narrow‑angle anatomy should be evaluated before dilation.

Mydriacyl is contraindicated in individuals with known hypersensitivity to tropicamide or any excipients in the formulation. It should be used with caution, or avoided, in patients with narrow‑angle or uncontrolled glaucoma, as dilation may precipitate angle‑closure attacks. Children and elderly patients may require closer monitoring due to increased sensitivity. The prescribing clinician must assess each patient’s ocular history before administration.